By

Gisela Pairo
Lucinda Cash-Gibson (VHIR), Juan M Pericàs (VHIR), Cécile Spiertz (Janssen), Edwin van de Ketterij EATRIS); Eva Molero (Teamit); Francesco Patalano (Novartis); Dipak Kalra (i~HD); Anton Ussi (EATRIS); Ann Van Dessel (Janssen), and Joan Genescà (VHIR) will present an e-Poster at the conference which will take place online during 11-12th November 2021. Organised by The European Public...
Read More
Complex Clinical Trials (CCTs) have the potential to accelerate drug development and enable patients to get timely access to transformative therapies. To continue generating innovative shared solutions for the use of CCTs, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has organised the virtual workshop “Accelerating Adoption of Complex Clinical Trials in Europe and...
Read More
EU-PEARL’s experience on advancing towards a new paradigm of clinical trials will be presented during TBScience event which will take place online next 19th – 22nd October in the context of the 52nd Union World Conference on Lung Health. Tobias Mielke (Scientific Director, Janssen), and Cecile Spiertz (Senior Director, External Innovation Clinical Trial Platforms, Janssen)...
Read More
Meyer received the award for his paper “Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials”. The prestigious Arthur-Linder-Prize is awarded every two years by the Austrian-Swiss Region of the International Biometric Society (IBS-ROeS) to support young scientists in honor of Prof. Arthur Linder for a research paper in the field of...
Read More
What started your scientific vocation? Ever since I was little, I have been drawn to scientific subjects. Even though I really had no idea of what science was, I chose to study biology at University mostly because it was something I was keen on learning. It was during my University studies that I first discovered...
Read More
In a conventional clinical trial, adult or paediatric, typically half of the participants receive the drug under investigation and half receive placebo or standard of care. If there are many trials in a disease area, it can be hard to find enough patients for all the trials taking place at a given time. Trials may...
Read More
By WP4 (Stefan M. Gold, Yanina Flossbach, Witte Hoogendijk, Christian Otte, Carmine Pariante, Toni Ramos-Quiroga) Depression, or “major depressive disorder” (MDD) as it is known by the medical community, is a serious and life-threatening condition with high rates of morbidity and a chronic disease course. It affects approximately 1 in 6 adults at some point...
Read More
Lucinda Cash-Gibson (VHIR) and Estefanía Cordero (EPF) will represent EU-PEARL in the XPatientBCN Congress which will take place online next 28th – 29th September. They will offer and overview of the project and the innovative framework of patient-centric collaborative platform trials EU-PEARL is developing to bring novel treatments and therapeutics to patients in a faster,...
Read More
Dr. Juan M Pericàs, hepatologist and public health expert at the Vall d’Hebron Hospital Campus (Barcelona) and EU-PEARL’s NASH work package leader, will present the “Challenges and clinical trial scenarios in NASH specific platform trials” at this year’s NAFLD Summit on behalf of WP6. The NAFLD Summit, which will be held on September 16-17 in...
Read More
EU-PEARL members, Lucinda Cash-Gibson (VHIR) and Francesco Patalano (Novartis) spoke to Hanna Balfour (European Pharmaceutical Review) about the need for more collaborative approaches in clinical research. They explained how public and private partners are working in this direction by building a patient centric framework to conduct adaptive platform trials, thus contributing to steer clinical research...
Read More
1 2 3 4 7

Sign up to stay informed


    We will process your data to deliver our quarterly updates to your inbox. You can view our Privacy Policy here or contact us at info@eu-pearl.eu